273 related articles for article (PubMed ID: 11854300)
21. Role of p53 transcription factor in determining the efficacy of telomerase inhibitors in cancer treatment.
Gala K; Jain M; Shah P; Pandey A; Garg M; Khattar E
Life Sci; 2024 Feb; 339():122416. PubMed ID: 38216120
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of telomerase causes vulnerability to endoplasmic reticulum stress-induced neuronal cell death.
Hosoi T; Nakatsu K; Shimamoto A; Tahara H; Ozawa K
Neurosci Lett; 2016 Aug; 629():241-244. PubMed ID: 27443785
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of telomerase by BIBR 1532 and related analogues.
Barma DK; Elayadi A; Falck JR; Corey DR
Bioorg Med Chem Lett; 2003 Apr; 13(7):1333-6. PubMed ID: 12657276
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment.
Ward RJ; Autexier C
Mol Pharmacol; 2005 Sep; 68(3):779-86. PubMed ID: 15939802
[TBL] [Abstract][Full Text] [Related]
25. Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors.
Piotrowska K; Kleideiter E; Mürdter TE; Taetz S; Baldes C; Schaefer U; Lehr CM; Klotz U
Lab Invest; 2005 Dec; 85(12):1565-9. PubMed ID: 16170334
[TBL] [Abstract][Full Text] [Related]
26. Potent inhibition of human telomerase by nitrostyrene derivatives.
Kim JH; Kim JH; Lee GE; Lee JE; Chung IK
Mol Pharmacol; 2003 May; 63(5):1117-24. PubMed ID: 12695540
[TBL] [Abstract][Full Text] [Related]
27. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
Rankin AM; Faller DV; Spanjaard RA
Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
[TBL] [Abstract][Full Text] [Related]
28. A highly selective telomerase inhibitor limiting human cancer cell proliferation.
Damm K; Hemmann U; Garin-Chesa P; Hauel N; Kauffmann I; Priepke H; Niestroj C; Daiber C; Enenkel B; Guilliard B; Lauritsch I; Müller E; Pascolo E; Sauter G; Pantic M; Martens UM; Wenz C; Lingner J; Kraut N; Rettig WJ; Schnapp A
EMBO J; 2001 Dec; 20(24):6958-68. PubMed ID: 11742973
[TBL] [Abstract][Full Text] [Related]
29. TERT inhibition leads to reduction of IL-6 expression induced by palmitic acid and interferes with the protective effects of tibolone in an astrocytic cell model.
González-Giraldo Y; Garzón-Benitez AV; Forero DA; Barreto GE
J Neuroendocrinol; 2019 Aug; 31(8):e12768. PubMed ID: 31278797
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of human telomerase activity by alterperylenol.
Togashi K; Kakeya H; Morishita M; Song YX; Osada H
Oncol Res; 1998; 10(9):449-53. PubMed ID: 10223620
[TBL] [Abstract][Full Text] [Related]
31. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
32. Down regulation of human telomerase reverse transcriptase (hTERT) expression by BIBR1532 in human glioblastoma LN18 cells.
Lavanya C; Venkataswamy MM; Sibin MK; Srinivas Bharath MM; Chetan GK
Cytotechnology; 2018 Aug; 70(4):1143-1154. PubMed ID: 29546682
[TBL] [Abstract][Full Text] [Related]
33. Investigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cells.
Doğan F; Özateş NP; Bağca BG; Abbaszadeh Z; Söğütlü F; Gasımlı R; Gündüz C; Biray Avcı Ç
J Cell Biochem; 2019 Feb; 120(2):1282-1293. PubMed ID: 30368861
[TBL] [Abstract][Full Text] [Related]
34. The Small Molecule BIBR1532 Exerts Potential Anti-cancer Activities in Preclinical Models of Feline Oral Squamous Cell Carcinoma Through Inhibition of Telomerase Activity and Down-Regulation of TERT.
Altamura G; Degli Uberti B; Galiero G; De Luca G; Power K; Licenziato L; Maiolino P; Borzacchiello G
Front Vet Sci; 2020; 7():620776. PubMed ID: 33553285
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the interaction between the nuclease and reverse transcriptase activity of the yeast telomerase complex.
Niu H; Xia J; Lue NF
Mol Cell Biol; 2000 Sep; 20(18):6806-15. PubMed ID: 10958677
[TBL] [Abstract][Full Text] [Related]
36. Potent Human Telomerase Inhibitors: Molecular Dynamic Simulations, Multiple Pharmacophore-Based Virtual Screening, and Biochemical Assays.
Shirgahi Talari F; Bagherzadeh K; Golestanian S; Jarstfer M; Amanlou M
J Chem Inf Model; 2015 Dec; 55(12):2596-610. PubMed ID: 26529120
[TBL] [Abstract][Full Text] [Related]
37. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
Kelland LR
Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
[TBL] [Abstract][Full Text] [Related]
38. A novel platinum compound inhibits telomerase activity in vitro and reduces telomere length in a human hepatoma cell line.
Furuta M; Nozawa K; Takemura M; Izuta S; Murate T; Tsuchiya M; Yoshida K; Taka N; Nimura Y; Yoshida S
Int J Cancer; 2003 May; 104(6):709-15. PubMed ID: 12640677
[TBL] [Abstract][Full Text] [Related]
39. Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.
Celeghin A; Giunco S; Freguja R; Zangrossi M; Nalio S; Dolcetti R; De Rossi A
Cell Death Dis; 2016 Dec; 7(12):e2562. PubMed ID: 28032863
[TBL] [Abstract][Full Text] [Related]
40. Combined treatment with emodin and a telomerase inhibitor induces significant telomere damage/dysfunction and cell death.
Liu R; Liu J; Wang S; Wang Y; Zhang T; Liu Y; Geng X; Wang F
Cell Death Dis; 2019 Jul; 10(7):527. PubMed ID: 31296842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
